Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study

Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study

Background: 3,4-diaminopyridine (3,4-DAP) can lead to clinical and electrophysiological improvement in myasthenic syndrome; it may thus represent a valuable therapeutic option for patients intolerant to pyridostigmine.Objective: to assess 3,4-diaminopyridine (3,4-DAP) effects and tolerability in pat...

Full description

Bibliographic Details
Main Authors: Marco Ceccanti, Laura Libonati, Gabriele Ruffolo, Pierangelo Cifelli, Federica Moret, Vittorio Frasca, Eleonora Palma, Maurizio Inghilleri, Chiara Cambieri
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Pharmacology
Subjects:
myasthenia gravis
acetylcholine receptors
repetitive nerve stimulation
quantitative myasthenia gravis test
anti-AChR antibodies
3,4-diaminopyridine (3,4-DAP)
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.982434/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.982434/full

Similar Items